Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
77 results about "Picornavirus" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A picornavirus is a virus belonging to the family Picornaviridae, a family of viruses in the order Picornavirales. Vertebrates, including humans, serve as natural hosts. Picornaviruses are nonenveloped viruses that represent a large family of small, cytoplasmic, plus-strand RNA (~7.5kb) viruses with a 30-nm icosahedral capsid. Its genome does not have a lipid membrane. Picornaviruses are found in mammals and birds. There are currently 80 species in this family, divided among 35 genera. Notable examples are Enterovirus (including Rhinovirus and Poliovirus), Aphthovirus, Cardiovirus, and Hepatovirus genera. The viruses in this family can cause a range of diseases including paralysis, meningitis, hepatitis and poliomyelitis. Picornaviruses are in Baltimore IV class. Their genome single-stranded (+) sense RNA is what functions as mRNA after entry into the cell and all viral mRNA synthesized is of genome polarity. The mRNA encodes RNA dependent RNA polymerase. This polymerase makes complementary minus strands of RNA, then uses them as templates to make more plus strands. So, an overview of the steps in picornavirus replication are in order: attachment, entry, translation, transcription/genome replication (one and the same process), assembly and exit.
Antisense antiviral agent and method for treating ssRNA viral infection
The invention provides antisense antiviral compounds and methods of their use in inhibition of growth of viruses of the picornavirus, calicivirus, togavirus and flavivirus families, as in treatment of a viral infection. The antisense antiviral compounds have morpholino subunits linked by uncharged phosphorodiamidate linkages interspersed with cationic phosphorodiamidate linkages.
Owner:SAREPTA THERAPEUTICS INC
Antisense antiviral agent and method for treating ssRNA viral infection
The invention provides antisense antiviral compounds and methods of their use in inhibition of growth of viruses of the picornavirus, calicivirus, togavirus and flavivirus families, as in treatment of a viral infection. The antisense antiviral compounds have morpholino subunits linked by uncharged phosphorodiamidate linkages interspersed with cationic phosphorodiamidate linkages.
Owner:SAREPTA THERAPEUTICS INC
Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses
ActiveUS20140243341A1Preventing and inhibiting replicationBiocideSsRNA viruses positive-senseEnterovirusDisease
Antiviral protease inhibitors, including peptidyl aldehydes, peptidyl α-ketoamides, peptidyl bisulfite salts, and peptidyl heterocycles, are disclosed, along with related antiviral compounds, and methods of using the same to treat or prevent viral infection and disease. The compounds possess broad-spectrum activity against viruses that belong to the picornavirus-like supercluster, which include important human and animal pathogens including noroviruses, enteroviruses, poliovirus, foot-and-mouth disease virus, hepatitis A virus, human rhinovirus (cause of common cold), human coronavirus (another cause of common cold), transmissible gastroenteritis virus, murine hepatitis virus, feline infectious peritonitis virus, and severe acute respiratory syndrome coronavirus.
Owner:WICHITA STATE UNIVERSITY +2
Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3c or 3c-like proteases of picornaviruses, caliciviruses and coronaviruses
Antiviral protease inhibitors, including macrocylic transition state inhibitors and peptidomimetics are disclosed, along with related antiviral compounds, and methods of using the same to treat or prevent viral infection and disease. The compounds possess broad-spectrum activity against viruses that belong to the picornavirus-like supercluster, which include important human and animal pathogens including noroviruses, sapoviruses, enteroviruses, poliovirus, foot-and-mouth disease virus, hepatitis A virus, human rhinovirus (cause of common cold), human coronavirus (another cause of common cold), transmissible gastroenteritis virus, murine hepatitis virus, feline infectious peritonitis virus, and severe acute respiratory syndrome coronavirus.
Owner:WICHITA STATE UNIVERSITY +1
Broad-spectrum antivirals against 3C or 3C-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses
Antiviral protease inhibitors, including peptidyl aldehydes, peptidyl α-ketoamides, peptidyl bisulfate salts, and peptidyl heterocycles, are disclosed, along with related antiviral compounds, and methods of using the same to treat or prevent viral infection and disease. The compounds possess broad-spectrum activity against viruses that belong to the picornavirus-like supercluster, which include important human and animal pathogens including noroviruses, enteroviruses, poliovirus, foot-and-mouth disease virus, hepatitis A virus, human rhinovirus (cause of common cold), human coronavirus (another cause of common cold), transmissible gastroenteritis virus, murine hepatitis virus, feline infectious peritonitis virus, and severe acute respiratory syndrome coronavirus.
Owner:WICHITA STATE UNIVERSITY +2
Recombinant poliovirus for the treatment of cancer
The present invention is directed to non-pathogenic, oncolytic, recombinant polioviruses for the treatment of various forms of malignant tumors. The recombinant polioviruses of the invention are those in which the internal ribosomal entry site (IRES) of the wild type poliovirus was exchanged with the IRES of other picornaviruses, and optionally P1, P3 or the 3'NTR thereof was exchanged with that of poliovirus Sabin type. More particularly, the present invention is directed to the administration of the non-pathogenic, oncolytic, recombinant poliovirus to the tumor directly, intrathecally or intravenously to cause tumor necrosis. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain. Astounding remissions in experimental animals have been demonstrated for the treatment of malignant glioblastoma multiforme, an almost universally fatal neoplasm of the central nervous system.
Owner:NEW YORK UNIV OF RES FOUND OF THE
Seneca valley virus based compositions and methods for treating disease
ActiveUS20060159659A1High therapeutic indexSafe and effective and new lineBiocideSsRNA viruses positive-senseAbnormal tissue growthProtein detection
The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
Owner:PERCEIVER PHARMA +1
Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, caliciviruses and coronaviruses
Antiviral protease inhibitors, including macrocylic transition state inhibitors and peptidomimetics are disclosed, along with related antiviral compounds, and methods of using the same to treat or prevent viral infection and disease. The compounds possess broad-spectrum activity against viruses that belong to the picornavirus-like supercluster, which include important human and animal pathogens including noroviruses, sapoviruses, enteroviruses, poliovirus, foot-and-mouth disease virus, hepatitis A virus, human rhinovirus (cause of common cold), human coronavirus (another cause of common cold), transmissible gastroenteritis virus, murine hepatitis virus, feline infectious peritonitis virus, and severe acute respiratory syndrome coronavirus.
Owner:THE WICHITA STATE UNIV +1
Seneca valley virus based compositions and methods for treating disease
The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus ('SVV'). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
Owner:NOVARTIS PHARM AG
Recombinant poliovirus for the treatment of cancer
The present invention is directed to non-pathogenic, oncolytic, recombinant polioviruses for the treatment of various forms of malignant tumors. The recombinant polioviruses of the invention are those in which the internal ribosomal entry site (IRES) of the wild type poliovirus was exchanged with the IRES of other picornaviruses, and optionally P1, P3 or the 3'NTR thereof was exchanged with that of poliovirus Sabin type. More particularly, the present invention is directed to the administration of the non-pathogenic, oncolytic, recombinant poliovirus to the tumor directly, intrathecally or intravenously to cause tumor necrosis. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain. Astounding remissions in experimental animals have been demonstrated for the treatment of malignant glioblastoma multiforme, an almost universally fatal neoplasm of the central nervous system.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK
Seneca valley virus based compositions and methods for treating disease
InactiveCN101448526ASimple and fast life cycleEasy to operateSugar derivativesGenetic material ingredientsViral nucleic acidTropism
The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus ('SVV'). The invention provides isolated SW nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of rumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SW nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
Owner:纽特罗佩克斯公司 +1
Anti-viral compound
The present invention relates to compounds of Formula (I), which inhibit the growth of picornaviruses, Hepatitus viruses, enteroviruses, cardioviruses, polioviruses, coxsackieviruses of the A and B groups, echo virus and Mengo virus. In said Formula, A is phenyl, pyridyl, substituted phenyl, substituted pyridyl, or benzyl; R is hydrogen, COR4 or COCF; X is N-OH, O or CHR1 R1 is hydrogen, halo, CN, C -C alkyl -C≡ CH, CO(C -C alkyl), CO (C -C alkyl), or CONR2R3 R2 and R3 are independently hydrogen or C -C alkyl; A' is hydrogen, halo, C -C alkyl, benzyl, naphthyl, thienyl, furyl, pyridyl, pyrollyl, COR4 S(O)nR4 or a group of formula (II); R4 is C -C alkyl, phenyl, or substituted phenyl; n is 0,1, or 2; R5 is independently at each occurance hydrogen or halo; m is 1,2,3, or 4; and R6 is hydrogen, halo, CF, OH, CO H, NH, NO, CONHOCH, C -C alkyl, or CO (C -C alkyl), C -C alkoxy; or pharmaceutically acceptable salts thereof.
Owner:ELI LILLY & CO
Method of producing virus-like particles of picornavirus using a small-ubiquitin-related fusion protein expression system
A method for producing picornaviral capsid protein complexes (e.g., picornavirus like particles) in E. coli using a small-ubiquitin-related fusion protein expression system and an E. coli strain used in practicing this method. Also disclosed is use of the picornaviral capsid protein complexes like thus prepared for eliciting immune responses.
Owner:ACAD SINIC
Modified Oncolytic Viruses
An isolated selected Picornavirus capable of lytically infecting or killing a cell substantially in the absence of intercellular adhesion molecule-1 (ICAM-1).
Owner:MERCK SHARP & DOHME LLC
Preparation of Soluble Capsid Proteins of Picornaviruses Using SUMO Fusion Technology
InactiveUS20090280531A1Simple and efficientSsRNA viruses positive-senseSugar derivativesFusion Protein ExpressionPicornavirus
A method of producing a soluble capsid protein of a picornavirus using a novel and efficient SUMO fusion protein expression system.
Owner:ACAD SINIC
Anti-picornaviral ligands via a combinatorial computational and synthetic approach
The present invention provides structure-based combinatorial libraries of compounds containing the functional group minima of picornaviruses including poliovirus and rhinovirus. The libraries can be used to screen for therapeutical antiviral compounds, e.g., anti-picornaviral capsid-binding compounds.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Method and composition for treatment of neoplasms
InactiveUS20100104578A1Enhances cell selectivity and or neoplasm targetingOrganic active ingredientsSsRNA viruses positive-senseTreated animalNeoplasm
The invention relates to methods of treating a neoplasm in an animal, in particular treating a neoplasm in a human, through the use of isolated nucleic acid sequence, including synthetic viral RNA and complementary DNA, derived from one or more Picornaviruses. The invention also relates to compositions of isolated nucleic acids derived from one or more Picornaviruses, and to the use of isolated nucleic acids derived from one or more Picornaviruses for the manufacture of a medicament for the treatment of neoplasms in a mammal.
Owner:SHAFREN DARREN RAYMOND
Picornavirus and uses thereof
InactiveUS20090275636A1Lower Level RequirementsDecrease in levelOrganic active ingredientsSsRNA viruses positive-senseNucleic acid sequencingImmunogenicity
The invention is directed to a a clade of newly isolated and identified picornaviruses associated with respiratory infection, and isolated nucleic acids sequences and peptides thereof. The invention also relates to antibodies against antigens derived from the picornavirus. The invention also relates to iRNAs which target nucleic acid sequences of the picornavirus. The invention is related to methods for detecting the presence or absence of picornavirus in a subject. The invention is also related to immunogenic compositions for inducing an immune response against picornavirus in a subject.
Owner:HEALTH RES INC +1
Enhanced expression of picornavirus proteins
InactiveUS20140271697A1Increase productionInduce immune responseSsRNA viruses negative-senseSsRNA viruses positive-senseDiseaseADAMTS Proteins
The disclosure provides fusion proteins containing N-terminal signal peptides fused to immunogenic polypeptides. The immunogenic polypeptides may be from viruses, bacteria, or fungi. The disclosure also provides elevated expression of the immunogenic polypeptides using the N-terminal signal peptide. The N-terminal signal peptides enhance synthesis of the protein, particularly where the protein is neither a secretory nor a transmembrane peptide. The fusion proteins may be used to diagnose disease and to induce immune responses.
Owner:NOVAVAX
Methods and compositions for treatment of hematologic cancers
The present invention relates to oncolytic picornaviruses and methods and compositions for treating subjects having hematologic cancers. These include methods and compositions for treatment of myeloma, using disclosed Picornavirus such as Coxsackievirus, in methods of direct or indirect administration to subjects and ex vivo purging of malignant cells within auto grafts prior to transplantation.
Owner:MERCK & CO INC
Vesicular stromatitis virus (VSV)
InactiveCN1496268ASsRNA viruses negative-sensePeptide/protein ingredientsHerpetic stomatitisNormal cell
The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterised by having low levels, or no PKR activity, or as being PKR- / -, STAT1- / - or both PKR- / - and STAT- / -. The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.
Owner:VIRUSTA BIOLOGICAL
Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
Compounds of formula (I), wherein the variables of the formula are as defined in this disclosure, can advantageously inhibit or block the biological activity of picornavirus 3C protease. These compounds, as well as pharmaceutical compositions containing these compounds, are suitable for treating patients or hosts infected with one or more picornaviruses, such as RVP. Intermediates and synthetic methods for the preparation of such compounds are also described.
Owner:AGOURON PHARMA INC
Seneca Valley virus based compositions and methods for treating disease
ActiveUS7638318B2Small and easily manipulatable genomeSimple and fast lifecycleBiocideSsRNA viruses positive-senseDiseaseTropism
The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
Owner:PERCEIVER PHARMA +1
Seneca valley virus based compositions and methods for treating disease
ActiveUS20100129325A1Small and easily manipulatable genomeSimple and fast lifecycleBiocideSsRNA viruses positive-senseDiseaseTropism
Owner:NOVARTIS AG +1
Pelodiscus sinensis picornavirus complete genome sequence and applications thereof
ActiveCN103387997AMicrobiological testing/measurementMicroorganism based processesNucleotide sequencingPicornavirus
The invention relates to a separated nucleic acid molecule having a nucleotide sequence shown as SEQ ID NO:1 or an antisense sequence of the SEQ ID NO:1. The nucleic acid molecule is derived from pelodiscus sinensis picornavirus strain CNSR2011. The nucleic acid molecule can be used for preparing primers, probes or kits, wherein the primers, the probes and the kits are used for detecting the pelodiscus sinensis picornavirus. The nucleic acid molecule can also be used for preparing a vaccine of the pelodiscus sinensis picornavirus, and an anti-pelodiscus sinensis picornavirus antibody.
Owner:ZHEJIANG INST OF FRESH WATER FISHERIES
Method of producing virus-like particles of picornavirus using a small-ubiquitin-related fusion protein expression system
A method for producing picornaviral capsid protein complexes (e.g., picornavirus like particles) in E. coli using a small-ubiquitin-related fusion protein expression system and an E. coli strain used in practicing this method. Also disclosed is use of the picornaviral capsid protein complexes like thus prepared for eliciting immune responses.
Owner:ACAD SINIC
Oncolytic virus
InactiveUS8147822B1Reduced effectivenessReduce riskSsRNA viruses negative-senseBiocideNormal cellPicornavirus
The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterized by having low levels, or no, PKR activity, or as being PKR− / −, STAT1− / − or both PKR− / − and STAT1− / −. The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.
Owner:WELLSTAT BIOLOGICS CORP
Antipicornaviral compounds, their preparation and use
InactiveUS6906198B1Highly effective for treating maladyUse in synthesisAnthracene dyesPeptides with abnormal peptide linkPicornavirusDrug biological activity
Peptido and peptidomimetic compounds of the formula: wherein the formula variables are as defined in the disclosure, advantageously inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with one or more picornaviruses, such as RVP. Intermediates and synthetic methods for preparing such compounds are also provided.
Owner:AGOURON PHARMA INC
Methods and compositions for treatment of hematologic cancers
The present invention relates to oncolytic Picornaviruses and methods and compositions for treating subjects having hematologic cancers. These include methods and compositions for treatment of myeloma, using disclosed Picornavirus such as Coxsackievirus, in methods of direct or indirect administration to subjects and ex vivo purging of malignant cells within auto grafts prior to transplantation.
Owner:MERCK SHARP & DOHME LLC
Component and method for treating viral disease
ActiveUS20150045318A1Preventing and alleviatingBiocideAntiviralsSingle-Stranded RNATherapeutic effect
A method for treating viral infection includes administering to a subject in need thereof a composition containing P2X receptor antagonists. The methods may achieve preventive or therapeutic effect on hand foot and mouth disease by inhibiting viruses. The P2X receptor antagonists can inhibit infection by a positive-sense single-stranded RNA picornavirus. The virus may be an enterovirus or a Coxsackie virus, such as human enterovirus 71. The P2X receptor antagonist may be PPADS, iso-PPADS, PPNDS, Suramin, NF023, TNP-ATP, NF279, NF157, Evans Blue, an analog thereof, a derivative thereof, or a pharmaceutically acceptable salt thereof.
Owner:HAINAN HONZ PHARMA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com